ErbB2 expression is correlated with increased survival of patients with osteosarcoma
Open Access
- 11 March 2002
- Vol. 94 (5), 1397-1404
- https://doi.org/10.1002/cncr.10360
Abstract
BACKGROUND Elevated ErbB2 expression and gene amplification have been shown to be associated with poor prognosis in many cancers. Recently, it has been demonstrated that overexpression of ErbB2 protein in osteosarcoma is associated with the presence of pulmonary metastasis and decreased survival. By contrast, a previous study showed that the expression of ErbB2 declines in individual osteosarcomas as they become metastatic. In the current study, the authors determined the relation between ErbB2 status and outcome in a large number of selected patients with high‐grade osteosarcoma. METHODS ErbB2 status was determined immunohistochemically in biopsy specimens of osteosarcoma of the extremities from 81 patients who were treated with surgery and chemotherapy. None of the patients had metastatic disease at presentation (Stage II), and all were followed‐up for at least five years. The ErbB2 status was analyzed in relation to the lengths of event‐free and overall survival. RESULTS Of the 81 tumors examined, 51 (61%) demonstrated high levels of ErbB2 expression. The presence of increased levels of ErbB2 in osteosarcoma was significantly associated with the increased probability of event‐free (72.2% v. 45.6% at 5 years, P = 0.03) and overall survival (79.7% v. 58.2% at 5 years, P = 0.03). Cox multivariate analysis showed that the risk of adverse events and death was increased substantially (rate ratio: 2.24 and 2.54; 95% confidence interval, 1.07–4.72 and 1.09–5.67, respectively) among patients with decreased levels of ErbB2 protein in tumor cells, as compared with patients who had increased levels of ErbB2 in tumor cells. CONCLUSIONS In patients with high‐grade osteosarcoma without metastatic disease at presentation and treated with surgery and chemotherapy, the presence of increased levels of ErbB2 in tumor cells is associated with a significantly increased probability of event‐free and overall survival. Further data are needed before this marker can be used in making clinical decisions. Cancer 2002;94:1397–404. © 2002 American Cancer Society. DOI 10.1002/cncr.10360This publication has 27 references indexed in Scilit:
- A Preliminary Report of Neoadjuvant Chemotherapy NSH-7 Study in Osteosarcoma: Preoperative Salvage Chemotherapy Based on Clinical Tumor Response and the Use of Granulocyte Colony-Stimulating FactorOncology, 1996
- Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expressionCarcinogenesis: Integrative Cancer Research, 1995
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991
- Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor functionCell, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- A System of Staging Musculoskeletal NeoplasmsPublished by Ovid Technologies (Wolters Kluwer Health) ,1986
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985